Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328973 | 1.00 | ALOX15 (0.48) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3327842 | 0.93 | ALOX15 (0.42) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3327838 | 0.93 | ALOX15 (0.42) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3332281 | 0.93 | ALOX15 (0.52) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3332277 | 0.93 | ALOX15 (0.52) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14268796 | 0.87 | ALOX15 (0.48) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3332355 | 0.87 | ALOX15 (0.52) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3332354 | 0.87 | ALOX15 (0.52) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5091931 | 0.85 | LMNA (0.45) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5091932 | 0.85 | LMNA (0.45) | ALOX15KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137627-A1 | 3-(2-Alkoxycarbonyloxy-Phenyl) Acrylic Acid Esters and Their Use as Precursors for the Delivery of Olfactory Compounds | GIVAUDAN SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20080269102-A1 | 3-(2-Alkoxycarbonyloxy-Phenyl) Acrylic Acid Esters And Their Use As Precursors For The Delivery Of Olfactory Compounds | GIVAUDAN SA (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1725515-A1 | 3-(2-ALKOXYCARBONYLOXY-PHENYL)ACRYLIC ACID ESTERS AND THEIR USE AS PRECURSORS FOR THE DELIVERY OF OLFACTORY COMPOUNDS | Givaudan SA (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005077881-A1 | 3-(2-ALKOXYCARBONYLOXY-PHENYL) ACRYLIC ACID ESTERS AND THEIR USE AS PRECURSORS FOR THE DELIVERY OF OLFACTORY COMPOUNDS | GIVAUDAN SA (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269102-A1 | 3-(2-Alkoxycarbonyloxy-Phenyl) Acrylic Acid Esters And Their Use As Precursors For The Delivery Of Olfactory Compounds | OR10J3, OR51E2, TAS2R43 | ALOX15 406/4885KDM4E 1839/4885ALDH1A1 158/4885 |
| US-20100137627-A1 | 3-(2-Alkoxycarbonyloxy-Phenyl) Acrylic Acid Esters and Their Use as Precursors for the Delivery of Olfactory Compounds | OR10J3, OR51E2, TAS2R43 | ALOX15 406/4885KDM4E 1839/4885ALDH1A1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.